当前蛋白身份：Q15910
重新检索
差异标签只比较当前检索结果；所有PDB和assembly原始记录仍分别保留。
相关结构差异明细
一行代表一个 PDB 条目中的一个 biological assembly；同一蛋白的多个单体会分别列出。
| PDB 条目 | Assembly / 聚集状态 | 构建体 | 突变与修饰 | 配体、离子与非聚合物 | 实验方法 | 实验环境 | 结构质量 |
|---|---|---|---|---|---|---|---|
| 4MI0 Human Enhancer of Zeste (Drosophila) Homolog 2(EZH2) 提交 2013-08-30 | Assembly 1 蛋白单体 单体；蛋白 × 1 PDB 声明：monomeric（1） 与蛋白数一致 |
链 A
520–746（227 aa）
片段：UNP residues 520-746
|
未记录 | ZN ZINC ION × 6 UNX UNKNOWN LIGAND × 4 | X-RAY DIFFRACTION |
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP；pH 7.5；291 K；20% PEG 3350, 0.2M Lithium Sulfate, 0.1M HEPES pH7.5, VAPOR DIFFUSION, HANGING DROP, temperature 291K
|
分辨率 2.00 Å R-free 0.239 |
| 4MI5 Crystal structure of the EZH2 SET domain 提交 2013-08-30 | Assembly 1 蛋白单体 单体；蛋白 × 1 PDB 声明：monomeric（1） 与蛋白数一致 |
链 A
521–746（226 aa）
片段：SET DOMAIN (UNP residues 521-746)
|
未记录 | SO4 SULFATE ION × 1 ZN ZINC ION × 6 | X-RAY DIFFRACTION |
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP；pH 6.5；294 K；100mM MES pH 6.5, 30% PEG MME 5K, 200mM Ammonium Sulfate, VAPOR DIFFUSION, SITTING DROP, temperature 294K
|
分辨率 2.00 Å R-free 0.257 |
| 5GSA EED in complex with an allosteric PRC2 inhibitor 提交 2016-08-15 | Assembly 1 蛋白异源复合物 异源复合物；蛋白 × 2 PDB 声明：dimeric（2） 与蛋白数一致 |
链 C
40–68（29 aa）
|
未记录 | 73K N-(furan-2-ylmethyl)-8-(4-methylsulfonylphenyl)-[1,2,4]triazolo[4,3-c]pyrimidin-5-amine × 1 | X-RAY DIFFRACTION |
X-ray结晶条件
EVAPORATION；pH 8；293 K；0.1 M TRIS, 16% PEG 8000
|
分辨率 2.49 Å R-free 0.255 |
| 5GSA EED in complex with an allosteric PRC2 inhibitor 提交 2016-08-15 | Assembly 2 蛋白异源复合物 异源复合物；蛋白 × 2 PDB 声明：dimeric（2） 与蛋白数一致 |
链 D
40–68（29 aa）
|
未记录 | 73K N-(furan-2-ylmethyl)-8-(4-methylsulfonylphenyl)-[1,2,4]triazolo[4,3-c]pyrimidin-5-amine × 1 | X-RAY DIFFRACTION |
X-ray结晶条件
EVAPORATION；pH 8；293 K；0.1 M TRIS, 16% PEG 8000
|
分辨率 2.49 Å R-free 0.255 |
| 5H14 EED in complex with an allosteric PRC2 inhibitor EED666 提交 2016-10-08 | Assembly 1 蛋白异源复合物 异源复合物；蛋白 × 2 PDB 声明：dimeric（2） 与蛋白数一致 |
链 D
40–68（29 aa）
片段：UNP residues 40-68
|
未记录 | GOL GLYCEROL × 1 LQB 2-[3-(3,5-dimethylpyrazol-1-yl)-4-nitro-phenyl]-3,4-dihydro-1H-isoquinoline × 1 | X-RAY DIFFRACTION |
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP；pH 8；293 K；0.1 M Tris, 16% PEG 8000, 10 mM beta-Nicotinamide mononucleotide
|
分辨率 1.90 Å R-free 0.223 |
| 5H14 EED in complex with an allosteric PRC2 inhibitor EED666 提交 2016-10-08 | Assembly 2 蛋白异源复合物 异源复合物；蛋白 × 2 PDB 声明：dimeric（2） 与蛋白数一致 |
链 C
40–68（29 aa）
片段：UNP residues 40-68
|
未记录 | GOL GLYCEROL × 1 LQB 2-[3-(3,5-dimethylpyrazol-1-yl)-4-nitro-phenyl]-3,4-dihydro-1H-isoquinoline × 1 | X-RAY DIFFRACTION |
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP；pH 8；293 K；0.1 M Tris, 16% PEG 8000, 10 mM beta-Nicotinamide mononucleotide
|
分辨率 1.90 Å R-free 0.223 |
| 5H15 EED in complex with PRC2 allosteric inhibitor EED709 提交 2016-10-08 | Assembly 1 蛋白异源复合物 异源复合物；蛋白 × 2 PDB 声明：dimeric（2） 与蛋白数一致 |
链 C
40–68（29 aa）
片段：UNP residues 40-68
|
未记录 | LQD (3R,4S)-1-[(2-methoxyphenyl)methyl]-N,N-dimethyl-4-(1-methylindol-3-yl)pyrrolidin-3-amine × 1 | X-RAY DIFFRACTION |
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP；pH 8；293 K；0.1 M Tris, 16% PEG 8000, 10 mM beta-Nicotinamide mononucleotide
|
分辨率 2.27 Å R-free 0.236 |
| 5H15 EED in complex with PRC2 allosteric inhibitor EED709 提交 2016-10-08 | Assembly 2 蛋白异源复合物 异源复合物；蛋白 × 2 PDB 声明：dimeric（2） 与蛋白数一致 |
链 D
40–68（29 aa）
片段：UNP residues 40-68
|
未记录 | LQD (3R,4S)-1-[(2-methoxyphenyl)methyl]-N,N-dimethyl-4-(1-methylindol-3-yl)pyrrolidin-3-amine × 1 | X-RAY DIFFRACTION |
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP；pH 8；293 K；0.1 M Tris, 16% PEG 8000, 10 mM beta-Nicotinamide mononucleotide
|
分辨率 2.27 Å R-free 0.236 |
| 5H17 EED in complex with PRC2 allosteric inhibitor EED210 提交 2016-10-08 | Assembly 1 蛋白异源复合物 异源复合物；蛋白 × 2 PDB 声明：dimeric（2） 与蛋白数一致 |
链 B
40–68（29 aa）
片段：UNP residues 40-68
|
未记录 | LQE (3R,4aS,10aS)-6-methoxy-3-[(3-methoxyphenyl)methyl]-1-methyl-3,4,4a,5,10,10a-hexahydro-2H-benzo[g]quinoline × 1 | X-RAY DIFFRACTION |
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP；pH 8；293 K；0.1 M Tris, 16% PEG 8000,10 mM beta-Nicotinamide mononucleotide
|
分辨率 2.30 Å R-free 0.239 |
| 5H19 EED in complex with PRC2 allosteric inhibitor EED162 提交 2016-10-08 | Assembly 1 蛋白异源复合物 异源复合物；蛋白 × 2 PDB 声明：dimeric（2） 与蛋白数一致 |
链 B
40–68（29 aa）
片段：UNP residues 40-68
|
未记录 | LQF 5-(furan-2-ylmethylamino)-9-(phenylmethyl)-8,10-dihydro-7H-[1,2,4]triazolo[3,4-a][2,7]naphthyridine-6-carbonitrile × 1 | X-RAY DIFFRACTION |
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP；pH 6；293 K；0.1 M Bis-Tris, 0.2 M MgCl2, 20% PEG 3350
|
分辨率 1.90 Å R-free 0.215 |
| 5H24 EED in complex with PRC2 allosteric inhibitor compound 8 提交 2016-10-14 | Assembly 1 蛋白异源复合物 异源复合物；蛋白 × 2 PDB 声明：dimeric（2） 与蛋白数一致 |
链 C
40–68（29 aa）
片段：UNP residues 40-68
|
未记录 | LQG 5-(furan-2-ylmethylamino)-[1,2,4]triazolo[4,3-a]pyridine-6-carbonitrile × 1 | X-RAY DIFFRACTION |
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP；pH 8；293 K；0.1 M Tris, 16% PEG 8000, 10 mM beta-Nicotinamide mononucleotide
|
分辨率 2.50 Å R-free 0.255 |
| 5H24 EED in complex with PRC2 allosteric inhibitor compound 8 提交 2016-10-14 | Assembly 2 蛋白异源复合物 异源复合物；蛋白 × 2 PDB 声明：dimeric（2） 与蛋白数一致 |
链 D
40–68（29 aa）
片段：UNP residues 40-68
|
未记录 | LQG 5-(furan-2-ylmethylamino)-[1,2,4]triazolo[4,3-a]pyridine-6-carbonitrile × 1 | X-RAY DIFFRACTION |
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP；pH 8；293 K；0.1 M Tris, 16% PEG 8000, 10 mM beta-Nicotinamide mononucleotide
|
分辨率 2.50 Å R-free 0.255 |
| 5H25 EED in complex with PRC2 allosteric inhibitor compound 11 提交 2016-10-14 | Assembly 1 蛋白异源复合物 异源复合物；蛋白 × 2 PDB 声明：dimeric（2） 与蛋白数一致 |
链 C
40–68（29 aa）
片段：UNP residues 40-68
|
未记录 | LQH 5-(2-fluorophenyl)-2,3-dihydroimidazo[2,1-a]isoquinoline × 1 | X-RAY DIFFRACTION |
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP；pH 8；293 K；0.1 M Tris, 16% PEG 8000, 10 mM beta-Nicotinamide mononucleotide
|
分辨率 2.88 Å R-free 0.274 |
| 5H25 EED in complex with PRC2 allosteric inhibitor compound 11 提交 2016-10-14 | Assembly 2 蛋白异源复合物 异源复合物；蛋白 × 2 PDB 声明：dimeric（2） 与蛋白数一致 |
链 D
40–68（29 aa）
片段：UNP residues 40-68
|
未记录 | LQH 5-(2-fluorophenyl)-2,3-dihydroimidazo[2,1-a]isoquinoline × 1 | X-RAY DIFFRACTION |
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP；pH 8；293 K；0.1 M Tris, 16% PEG 8000, 10 mM beta-Nicotinamide mononucleotide
|
分辨率 2.88 Å R-free 0.274 |
| 5HYN Structure of Human Polycomb Repressive Complex 2 (PRC2) with oncogenic histone H3K27M peptide 提交 2016-02-01 | Assembly 1 蛋白异源复合物 异源复合物；蛋白 × 5 PDB 声明：pentameric（5） 与蛋白数一致 |
链 A
1–746（746 aa）
|
未记录 | ZN ZINC ION × 8 SAH S-ADENOSYL-L-HOMOCYSTEINE × 1 | X-RAY DIFFRACTION |
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP；pH 6.5；291 K；25% PEG3350, 400mM Ammonian Citrate pH6.5
|
分辨率 2.95 Å R-free 0.273 |
| 5HYN Structure of Human Polycomb Repressive Complex 2 (PRC2) with oncogenic histone H3K27M peptide 提交 2016-02-01 | Assembly 2 蛋白异源复合物 异源复合物；蛋白 × 5 PDB 声明：pentameric（5） 与蛋白数一致 |
链 F
1–746（746 aa）
|
未记录 | ZN ZINC ION × 8 SAH S-ADENOSYL-L-HOMOCYSTEINE × 1 | X-RAY DIFFRACTION |
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP；pH 6.5；291 K；25% PEG3350, 400mM Ammonian Citrate pH6.5
|
分辨率 2.95 Å R-free 0.273 |
| 5HYN Structure of Human Polycomb Repressive Complex 2 (PRC2) with oncogenic histone H3K27M peptide 提交 2016-02-01 | Assembly 3 蛋白异源复合物 异源复合物；蛋白 × 5 PDB 声明：pentameric（5） 与蛋白数一致 |
链 K
1–746（746 aa）
|
未记录 | ZN ZINC ION × 8 SAH S-ADENOSYL-L-HOMOCYSTEINE × 1 | X-RAY DIFFRACTION |
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP；pH 6.5；291 K；25% PEG3350, 400mM Ammonian Citrate pH6.5
|
分辨率 2.95 Å R-free 0.273 |
| 5HYN Structure of Human Polycomb Repressive Complex 2 (PRC2) with oncogenic histone H3K27M peptide 提交 2016-02-01 | Assembly 4 蛋白异源复合物 异源复合物；蛋白 × 5 PDB 声明：pentameric（5） 与蛋白数一致 |
链 Q
1–746（746 aa）
|
未记录 | ZN ZINC ION × 8 SAH S-ADENOSYL-L-HOMOCYSTEINE × 1 | X-RAY DIFFRACTION |
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP；pH 6.5；291 K；25% PEG3350, 400mM Ammonian Citrate pH6.5
|
分辨率 2.95 Å R-free 0.273 |
| 5HYN Structure of Human Polycomb Repressive Complex 2 (PRC2) with oncogenic histone H3K27M peptide 提交 2016-02-01 | Assembly 5 蛋白异源复合物 异源复合物；蛋白 × 4 PDB 声明：tetrameric（4） 与蛋白数一致 |
链 A
1–746（746 aa）
|
未记录 | ZN ZINC ION × 8 SAH S-ADENOSYL-L-HOMOCYSTEINE × 1 | X-RAY DIFFRACTION |
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP；pH 6.5；291 K；25% PEG3350, 400mM Ammonian Citrate pH6.5
|
分辨率 2.95 Å R-free 0.273 |
| 5HYN Structure of Human Polycomb Repressive Complex 2 (PRC2) with oncogenic histone H3K27M peptide 提交 2016-02-01 | Assembly 6 蛋白异源复合物 异源复合物；蛋白 × 4 PDB 声明：tetrameric（4） 与蛋白数一致 |
链 F
1–746（746 aa）
|
未记录 | ZN ZINC ION × 8 SAH S-ADENOSYL-L-HOMOCYSTEINE × 1 | X-RAY DIFFRACTION |
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP；pH 6.5；291 K；25% PEG3350, 400mM Ammonian Citrate pH6.5
|
分辨率 2.95 Å R-free 0.273 |
| 5HYN Structure of Human Polycomb Repressive Complex 2 (PRC2) with oncogenic histone H3K27M peptide 提交 2016-02-01 | Assembly 7 蛋白异源复合物 异源复合物；蛋白 × 4 PDB 声明：tetrameric（4） 与蛋白数一致 |
链 K
1–746（746 aa）
|
未记录 | ZN ZINC ION × 8 SAH S-ADENOSYL-L-HOMOCYSTEINE × 1 | X-RAY DIFFRACTION |
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP；pH 6.5；291 K；25% PEG3350, 400mM Ammonian Citrate pH6.5
|
分辨率 2.95 Å R-free 0.273 |
| 5HYN Structure of Human Polycomb Repressive Complex 2 (PRC2) with oncogenic histone H3K27M peptide 提交 2016-02-01 | Assembly 8 蛋白异源复合物 异源复合物；蛋白 × 4 PDB 声明：tetrameric（4） 与蛋白数一致 |
链 Q
1–746（746 aa）
|
未记录 | ZN ZINC ION × 8 SAH S-ADENOSYL-L-HOMOCYSTEINE × 1 | X-RAY DIFFRACTION |
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP；pH 6.5；291 K；25% PEG3350, 400mM Ammonian Citrate pH6.5
|
分辨率 2.95 Å R-free 0.273 |
| 5IJ7 Structure of Hs/AcPRC2 in complex with a pyridone inhibitor 提交 2016-03-01 | Assembly 1 信息不足 异源复合物；蛋白 × 3 PDB 声明：trimeric（3） 与蛋白数一致 |
链 A
390–707（318 aa）
|
未记录 | 6BN 5,8-dichloro-2-[(4-ethyl-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-7-({1-[(2R)-2-hydroxypropanoyl]piperidin-4-yl}oxy)-3,4-dihydroisoquinolin-1(2H)-one × 1 ZN ZINC ION × 7 | X-RAY DIFFRACTION |
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP；pH 6.6；286 K；24.0 %w/v PEG monomethyl ether 2000,
0.0050 M TCEP hydrochloride, 0.1 M Bis_tris (pH 6.60)
|
分辨率 2.62 Å R-free 0.238 |
| 5IJ7 Structure of Hs/AcPRC2 in complex with a pyridone inhibitor 提交 2016-03-01 | Assembly 2 信息不足 异源复合物；蛋白 × 3 PDB 声明：trimeric（3） 与蛋白数一致 |
链 B
390–707（318 aa）
|
未记录 | 6BN 5,8-dichloro-2-[(4-ethyl-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-7-({1-[(2R)-2-hydroxypropanoyl]piperidin-4-yl}oxy)-3,4-dihydroisoquinolin-1(2H)-one × 1 ZN ZINC ION × 7 | X-RAY DIFFRACTION |
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP；pH 6.6；286 K；24.0 %w/v PEG monomethyl ether 2000,
0.0050 M TCEP hydrochloride, 0.1 M Bis_tris (pH 6.60)
|
分辨率 2.62 Å R-free 0.238 |
| 5IJ8 Structure of the primary oncogenic mutant Y641N Hs/AcPRC2 in complex with a pyridone inhibitor 提交 2016-03-01 | Assembly 1 信息不足 异源复合物；蛋白 × 3 PDB 声明：trimeric（3） 与蛋白数一致 |
链 A
390–707（318 aa）
|
未记录 | 6BN 5,8-dichloro-2-[(4-ethyl-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-7-({1-[(2R)-2-hydroxypropanoyl]piperidin-4-yl}oxy)-3,4-dihydroisoquinolin-1(2H)-one × 1 ZN ZINC ION × 7 | X-RAY DIFFRACTION |
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP；pH 5.8；286 K；24.0 %w/v PEG monomethyl ether 2000, 0.0050 M TCEP hydrochloride, 0.1 M MES (pH 5.80)
|
分辨率 2.99 Å R-free 0.240 |
| 5IJ8 Structure of the primary oncogenic mutant Y641N Hs/AcPRC2 in complex with a pyridone inhibitor 提交 2016-03-01 | Assembly 2 信息不足 异源复合物；蛋白 × 3 PDB 声明：trimeric（3） 与蛋白数一致 |
链 B
390–707（318 aa）
|
未记录 | 6BN 5,8-dichloro-2-[(4-ethyl-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-7-({1-[(2R)-2-hydroxypropanoyl]piperidin-4-yl}oxy)-3,4-dihydroisoquinolin-1(2H)-one × 1 ZN ZINC ION × 7 | X-RAY DIFFRACTION |
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP；pH 5.8；286 K；24.0 %w/v PEG monomethyl ether 2000, 0.0050 M TCEP hydrochloride, 0.1 M MES (pH 5.80)
|
分辨率 2.99 Å R-free 0.240 |
| 5LS6 Structure of Human Polycomb Repressive Complex 2 (PRC2) with inhibitor 提交 2016-08-22 | Assembly 1 蛋白异源复合物 异源复合物；蛋白 × 4 PDB 声明：tetrameric（4） 与蛋白数一致 |
链 A
1–182（182 aa）
链 A
211–385（175 aa）
链 A
421–746（326 aa）
|
未记录 | ZN ZINC ION × 8 74D 1-[(1~{R})-1-[1-[2,2-bis(fluoranyl)propyl]piperidin-4-yl]ethyl]-~{N}-[(4-methoxy-6-methyl-2-oxidanylidene-3~{H}-pyridin-3-yl)methyl]-2-methyl-indole-3-carboxamide × 1 | X-RAY DIFFRACTION |
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP；pH 6.67；291 K；24% PEG3350, 400mM Ammonian Citrate pH6.67
|
分辨率 3.47 Å R-free 0.299 |
| 5LS6 Structure of Human Polycomb Repressive Complex 2 (PRC2) with inhibitor 提交 2016-08-22 | Assembly 2 蛋白异源复合物 异源复合物；蛋白 × 4 PDB 声明：tetrameric（4） 与蛋白数一致 |
链 D
1–182（182 aa）
链 D
211–385（175 aa）
链 D
421–746（326 aa）
|
未记录 | ZN ZINC ION × 8 74D 1-[(1~{R})-1-[1-[2,2-bis(fluoranyl)propyl]piperidin-4-yl]ethyl]-~{N}-[(4-methoxy-6-methyl-2-oxidanylidene-3~{H}-pyridin-3-yl)methyl]-2-methyl-indole-3-carboxamide × 1 | X-RAY DIFFRACTION |
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP；pH 6.67；291 K；24% PEG3350, 400mM Ammonian Citrate pH6.67
|
分辨率 3.47 Å R-free 0.299 |
| 5LS6 Structure of Human Polycomb Repressive Complex 2 (PRC2) with inhibitor 提交 2016-08-22 | Assembly 3 蛋白异源复合物 异源复合物；蛋白 × 4 PDB 声明：tetrameric（4） 与蛋白数一致 |
链 G
1–182（182 aa）
链 G
211–385（175 aa）
链 G
421–746（326 aa）
|
未记录 | ZN ZINC ION × 8 74D 1-[(1~{R})-1-[1-[2,2-bis(fluoranyl)propyl]piperidin-4-yl]ethyl]-~{N}-[(4-methoxy-6-methyl-2-oxidanylidene-3~{H}-pyridin-3-yl)methyl]-2-methyl-indole-3-carboxamide × 1 | X-RAY DIFFRACTION |
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP；pH 6.67；291 K；24% PEG3350, 400mM Ammonian Citrate pH6.67
|
分辨率 3.47 Å R-free 0.299 |
| 5LS6 Structure of Human Polycomb Repressive Complex 2 (PRC2) with inhibitor 提交 2016-08-22 | Assembly 4 蛋白异源复合物 异源复合物；蛋白 × 4 PDB 声明：tetrameric（4） 与蛋白数一致 |
链 J
1–182（182 aa）
链 J
211–385（175 aa）
链 J
421–746（326 aa）
|
未记录 | ZN ZINC ION × 8 74D 1-[(1~{R})-1-[1-[2,2-bis(fluoranyl)propyl]piperidin-4-yl]ethyl]-~{N}-[(4-methoxy-6-methyl-2-oxidanylidene-3~{H}-pyridin-3-yl)methyl]-2-methyl-indole-3-carboxamide × 1 | X-RAY DIFFRACTION |
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP；pH 6.67；291 K；24% PEG3350, 400mM Ammonian Citrate pH6.67
|
分辨率 3.47 Å R-free 0.299 |
| 5U5T Crystal structure of EED in complex with H3K27Me3 peptide and 3-(benzo[d][1,3]dioxol-4-ylmethyl)piperidine-1-carboximidamide 提交 2016-12-07 | Assembly 1 蛋白异源复合物 异源复合物；蛋白 × 2 PDB 声明：dimeric（2） 与蛋白数一致 |
链 C
39–68（30 aa）
片段：UNP residues 39-68
|
未记录 | 7W7 (3R)-3-[(2H-1,3-benzodioxol-4-yl)methyl]piperidine-1-carboximidamide × 1 | X-RAY DIFFRACTION |
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP；291 K；Using a PEG/salt combination as a precipitant. Briefly, EED was incubated with 10 mM B-nicotinamide adenine dinucleotide hydrate, 2 mM of a tightly binding proprietary compound, and 0.5 mM of a synthesized peptide which comprises the helix on EZH2 which interacts with EED. The crystals were grown using the vapor diffusion method. One uL of the protein mixture was combined with 1 uL of a precipitant comprised of 20% (w/v) PEG3350, 0.2 M potassium iodide, and 0.1M Tris-HCl, pH 8.5, on a cover slip which was suspended over a reservoir comprised of 0.5 mL of precipitant at 18 Celsius and sealed. The crystals grew in 4-6 days at 18 Celsius and then harvested and soaked in defined drops consisting of 30 uL of precipitant and 2 mM of compound for 24 h. Crystals were cryopreserved for data collection using a cryosolution consisting of 30% PEG 400 (v/v), 20% (w/v) PEG 3350, 0.2 M potassium iodide, and 0.1M Tris-HCl, pH 8.5
|
分辨率 1.60 Å R-free 0.200 |
| 5U5T Crystal structure of EED in complex with H3K27Me3 peptide and 3-(benzo[d][1,3]dioxol-4-ylmethyl)piperidine-1-carboximidamide 提交 2016-12-07 | Assembly 2 蛋白异源复合物 异源复合物；蛋白 × 2 PDB 声明：dimeric（2） 与蛋白数一致 |
链 D
39–68（30 aa）
片段：UNP residues 39-68
|
未记录 | 7W7 (3R)-3-[(2H-1,3-benzodioxol-4-yl)methyl]piperidine-1-carboximidamide × 1 YT3 YTTRIUM (III) ION × 2 | X-RAY DIFFRACTION |
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP；291 K；Using a PEG/salt combination as a precipitant. Briefly, EED was incubated with 10 mM B-nicotinamide adenine dinucleotide hydrate, 2 mM of a tightly binding proprietary compound, and 0.5 mM of a synthesized peptide which comprises the helix on EZH2 which interacts with EED. The crystals were grown using the vapor diffusion method. One uL of the protein mixture was combined with 1 uL of a precipitant comprised of 20% (w/v) PEG3350, 0.2 M potassium iodide, and 0.1M Tris-HCl, pH 8.5, on a cover slip which was suspended over a reservoir comprised of 0.5 mL of precipitant at 18 Celsius and sealed. The crystals grew in 4-6 days at 18 Celsius and then harvested and soaked in defined drops consisting of 30 uL of precipitant and 2 mM of compound for 24 h. Crystals were cryopreserved for data collection using a cryosolution consisting of 30% PEG 400 (v/v), 20% (w/v) PEG 3350, 0.2 M potassium iodide, and 0.1M Tris-HCl, pH 8.5
|
分辨率 1.60 Å R-free 0.200 |
| 5U62 Crystal structure of EED in complex with H3K27Me3 peptide and 6-(benzo[d][1,3]dioxol-4-ylmethyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-3-amine 提交 2016-12-07 | Assembly 1 蛋白异源复合物 异源复合物；蛋白 × 2 PDB 声明：dimeric（2） 与蛋白数一致 |
链 C
39–68（30 aa）
片段：UNP residues 39-68
|
未记录 | GOL GLYCEROL × 1 YT3 YTTRIUM (III) ION × 2 7WD (6S)-6-[(2H-1,3-benzodioxol-4-yl)methyl]-5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-3-amine × 1 | X-RAY DIFFRACTION |
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP；291 K；Using a PEG/salt combination as a precipitant. Briefly, EED was incubated with 10 mM B-nicotinamide adenine dinucleotide hydrate, 2 mM of a tightly binding proprietary compound, and 0.5 mM of a synthesized peptide which comprises the helix on EZH2 which interacts with EED. The crystals were grown using the vapor diffusion method. One uL of the protein mixture was combined with 1 uL of a precipitant comprised of 20% (w/v) PEG3350, 0.2 M potassium iodide, and 0.1M Tris-HCl, pH 8.5, on a cover slip which was suspended over a reservoir comprised of 0.5 mL of precipitant at 18 Celsius and sealed. The crystals grew in 4-6 days at 18 Celsius and then harvested and soaked in defined drops consisting of 30 uL of precipitant and 2 mM of compound for 24 h. Crystals were cryopreserved for data collection using a cryosolution consisting of 30% PEG 400 (v/v), 20% (w/v) PEG 3350, 0.2 M potassium iodide, and 0.1M Tris-HCl, pH 8.5.
|
分辨率 1.90 Å R-free 0.208 |
| 5U62 Crystal structure of EED in complex with H3K27Me3 peptide and 6-(benzo[d][1,3]dioxol-4-ylmethyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-3-amine 提交 2016-12-07 | Assembly 2 蛋白异源复合物 异源复合物；蛋白 × 2 PDB 声明：dimeric（2） 与蛋白数一致 |
链 D
39–68（30 aa）
片段：UNP residues 39-68
|
未记录 | 7WD (6S)-6-[(2H-1,3-benzodioxol-4-yl)methyl]-5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-3-amine × 1 | X-RAY DIFFRACTION |
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP；291 K；Using a PEG/salt combination as a precipitant. Briefly, EED was incubated with 10 mM B-nicotinamide adenine dinucleotide hydrate, 2 mM of a tightly binding proprietary compound, and 0.5 mM of a synthesized peptide which comprises the helix on EZH2 which interacts with EED. The crystals were grown using the vapor diffusion method. One uL of the protein mixture was combined with 1 uL of a precipitant comprised of 20% (w/v) PEG3350, 0.2 M potassium iodide, and 0.1M Tris-HCl, pH 8.5, on a cover slip which was suspended over a reservoir comprised of 0.5 mL of precipitant at 18 Celsius and sealed. The crystals grew in 4-6 days at 18 Celsius and then harvested and soaked in defined drops consisting of 30 uL of precipitant and 2 mM of compound for 24 h. Crystals were cryopreserved for data collection using a cryosolution consisting of 30% PEG 400 (v/v), 20% (w/v) PEG 3350, 0.2 M potassium iodide, and 0.1M Tris-HCl, pH 8.5.
|
分辨率 1.90 Å R-free 0.208 |
| 5WG6 Human Polycomb Repressive Complex 2 in complex with GSK126 inhibitor 提交 2017-07-13 | Assembly 1 信息不足 异源复合物；蛋白 × 2 PDB 声明：dimeric（2） 与蛋白数一致 |
链 A
2–182（181 aa）
链 A
196–385（190 aa）
链 A
421–746（326 aa）
|
未记录 | ZN ZINC ION × 8 A9G 1-[(2S)-butan-2-yl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-3-methyl-6-[6-(piperazin-1-yl)pyridin-3-yl]-1H-indole-4-carboxamide × 1 | X-RAY DIFFRACTION |
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP；pH 7.2；298 K；200 mM ammonium citrate pH 7.2, 16% PEG 3350
|
分辨率 3.90 Å R-free 0.300 |
| 5WG6 Human Polycomb Repressive Complex 2 in complex with GSK126 inhibitor 提交 2017-07-13 | Assembly 2 信息不足 异源复合物；蛋白 × 2 PDB 声明：dimeric（2） 与蛋白数一致 |
链 C
2–182（181 aa）
链 C
196–385（190 aa）
链 C
421–746（326 aa）
|
未记录 | ZN ZINC ION × 8 | X-RAY DIFFRACTION |
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP；pH 7.2；298 K；200 mM ammonium citrate pH 7.2, 16% PEG 3350
|
分辨率 3.90 Å R-free 0.300 |
| 5WUK Crystal structure of EED [G255D] in complex with EZH2 peptide and EED226 compound 提交 2016-12-19 | Assembly 1 蛋白异源复合物 异源复合物；蛋白 × 2 PDB 声明：dimeric（2） 与蛋白数一致 |
链 B
41–68（28 aa）
片段：UNP residues 41-68
|
未记录 | GOL GLYCEROL × 1 73K N-(furan-2-ylmethyl)-8-(4-methylsulfonylphenyl)-[1,2,4]triazolo[4,3-c]pyrimidin-5-amine × 1 | X-RAY DIFFRACTION |
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP；293 K；10% polyethylene glycol (PEG) 6000, 0.1M Bicine(pH9.0)
|
分辨率 2.03 Å R-free 0.191 |
| 6C23 Cryo-EM structure of PRC2 bound to cofactors AEBP2 and JARID2 in the Compact Active State 提交 2018-01-05 | Assembly 1 蛋白异源复合物 异源复合物；蛋白 × 12 PDB 声明：dodecameric（12） 与蛋白数一致 |
链 C
1–746（746 aa）
链 K
1–746（746 aa）
|
未记录 | 未记录非水小分子 | ELECTRON MICROSCOPY |
cryo-EM缓冲液
pH 7.9
cryo-EM玻璃化条件
冷冻剂 ETHANE
|
分辨率 3.90 Å |
| 6C24 Cryo-EM structure of PRC2 bound to cofactors AEBP2 and JARID2 in the Extended Active State 提交 2018-01-06 | Assembly 1 蛋白异源复合物 异源复合物；蛋白 × 12 PDB 声明：dodecameric（12） 与蛋白数一致 |
链 C
1–746（746 aa）
链 K
1–746（746 aa）
|
未记录 | 未记录非水小分子 | ELECTRON MICROSCOPY |
cryo-EM缓冲液
pH 7.9
cryo-EM玻璃化条件
冷冻剂 ETHANE
|
分辨率 3.50 Å |
| 6LO2 Crystal structure of EED in complex with EZH2 peptide and compound 11# 提交 2020-01-02 | Assembly 1 蛋白异源复合物 异源复合物；蛋白 × 2 PDB 声明：dimeric（2） 与蛋白数一致 |
链 C
40–68（29 aa）
|
未记录 | EJU 8-[4-[(dimethylamino)methyl]phenyl]-N-[(2-methoxyphenyl)methyl]-[1,2,4]triazolo[4,3-a]pyridin-5-amine × 1 | X-RAY DIFFRACTION |
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP；294 K；0.1 M TRIS pH 8.0, 15.6% PEG 8000
|
分辨率 2.21 Å R-free 0.232 |
| 6LO2 Crystal structure of EED in complex with EZH2 peptide and compound 11# 提交 2020-01-02 | Assembly 2 蛋白异源复合物 异源复合物；蛋白 × 2 PDB 声明：dimeric（2） 与蛋白数一致 |
链 D
40–68（29 aa）
|
未记录 | EJU 8-[4-[(dimethylamino)methyl]phenyl]-N-[(2-methoxyphenyl)methyl]-[1,2,4]triazolo[4,3-a]pyridin-5-amine × 1 | X-RAY DIFFRACTION |
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP；294 K；0.1 M TRIS pH 8.0, 15.6% PEG 8000
|
分辨率 2.21 Å R-free 0.232 |
| 6U4Y Crystal Structure of an EZH2-EED Complex in an Oligomeric State 提交 2019-08-26 | Assembly 1 蛋白异源复合物 异源复合物；蛋白 × 6 PDB 声明：hexameric（6） 与蛋白数一致 |
链 A
2–182（181 aa）
片段：UNP residues 2-182, linker, UNP residues 220-257
链 A
220–257（38 aa）
片段：UNP residues 2-182, linker, UNP residues 220-257
链 B
2–182（181 aa）
片段：UNP residues 2-182, linker, UNP residues 220-257
链 B
220–257（38 aa）
片段：UNP residues 2-182, linker, UNP residues 220-257
链 C
2–182（181 aa）
片段：UNP residues 2-182, linker, UNP residues 220-257
链 C
220–257（38 aa）
片段：UNP residues 2-182, linker, UNP residues 220-257
|
未记录 | 未记录非水小分子 | X-RAY DIFFRACTION |
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP；298 K；1 M sodium/potassium tartrate, 0.2 M lithium sulfate, 0.1 M Tris-HCl, pH 7.0
|
分辨率 2.91 Å R-free 0.224 |
| 6WKR PRC2-AEBP2-JARID2 bound to H2AK119ub1 nucleosome 提交 2020-04-16 | Assembly 1 蛋白–DNA 异源复合物；蛋白 × 17 PDB 声明：octadecameric（18） 与全部聚合物一致 |
链 C
1–746（746 aa）
|
未记录 | MG MAGNESIUM ION × 1 SAH S-ADENOSYL-L-HOMOCYSTEINE × 1 ZN ZINC ION × 1 | ELECTRON MICROSCOPY |
cryo-EM缓冲液
pH 7.9
cryo-EM玻璃化条件
冷冻剂 ETHANE
|
分辨率 3.50 Å |
| 7QJG EED in complex with PRC2 allosteric inhibitor compound 6 提交 2021-12-16 | Assembly 1 蛋白异源复合物 异源复合物；蛋白 × 2 PDB 声明：dimeric（2） 与蛋白数一致 |
链 D
40–68（29 aa）
|
未记录 | CL CHLORIDE ION × 2 EKR N-(2,3-dihydro-1-benzofuran-7-ylmethyl)-8-[4-[(dimethylamino)methyl]phenyl]-[1,2,4]triazolo[4,3-c]pyrimidin-5-amine × 1 | X-RAY DIFFRACTION |
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP；293 K；0.1 M Tris pH 8.0, 16% PEG 8000
|
分辨率 1.80 Å R-free 0.218 |
| 7QJG EED in complex with PRC2 allosteric inhibitor compound 6 提交 2021-12-16 | Assembly 2 蛋白异源复合物 异源复合物；蛋白 × 2 PDB 声明：dimeric（2） 与蛋白数一致 |
链 C
40–68（29 aa）
|
未记录 | CL CHLORIDE ION × 2 EKR N-(2,3-dihydro-1-benzofuran-7-ylmethyl)-8-[4-[(dimethylamino)methyl]phenyl]-[1,2,4]triazolo[4,3-c]pyrimidin-5-amine × 1 | X-RAY DIFFRACTION |
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP；293 K；0.1 M Tris pH 8.0, 16% PEG 8000
|
分辨率 1.80 Å R-free 0.218 |
| 7QJU EED in complex with PRC2 allosteric inhibitor compound 7 提交 2021-12-17 | Assembly 1 蛋白异源复合物 异源复合物；蛋白 × 2 PDB 声明：dimeric（2） 与蛋白数一致 |
链 C
40–68（29 aa）
|
未记录 | CL CHLORIDE ION × 2 EKF N-(2,3-dihydro-1-benzofuran-4-ylmethyl)-8-[4-[(dimethylamino)methyl]phenyl]-[1,2,4]triazolo[4,3-c]pyrimidin-5-amine × 1 | X-RAY DIFFRACTION |
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP；293 K；0.1 M Tris pH 8.0, 16% PEG 8000
|
分辨率 1.80 Å R-free 0.213 |
| 7QJU EED in complex with PRC2 allosteric inhibitor compound 7 提交 2021-12-17 | Assembly 2 蛋白异源复合物 异源复合物；蛋白 × 2 PDB 声明：dimeric（2） 与蛋白数一致 |
链 D
40–68（29 aa）
|
未记录 | CL CHLORIDE ION × 2 EKF N-(2,3-dihydro-1-benzofuran-4-ylmethyl)-8-[4-[(dimethylamino)methyl]phenyl]-[1,2,4]triazolo[4,3-c]pyrimidin-5-amine × 1 | X-RAY DIFFRACTION |
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP；293 K；0.1 M Tris pH 8.0, 16% PEG 8000
|
分辨率 1.80 Å R-free 0.213 |
| 7QK4 EED in complex with PRC2 allosteric inhibitor compound 22 (MAK683) 提交 2021-12-17 | Assembly 1 蛋白异源复合物 异源复合物；蛋白 × 2 PDB 声明：dimeric（2） 与蛋白数一致 |
链 B
40–68（29 aa）
|
未记录 | CL CHLORIDE ION × 3 EJR N-[(5-fluoranyl-2,3-dihydro-1-benzofuran-4-yl)methyl]-8-(2-methylpyridin-3-yl)-[1,2,4]triazolo[4,3-c]pyrimidin-5-amine × 1 | X-RAY DIFFRACTION |
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP；293 K；0.1 M Bis-Tris pH 6.0, 0.2 M MgCl2, 20% PEG 3350
|
分辨率 1.60 Å R-free 0.206 |
| 8EQV Cryo-EM structure of PRC2 in complex with the long isoform of AEBP2 提交 2022-10-09 | Assembly 1 蛋白异源复合物 异源复合物；蛋白 × 5 PDB 声明：pentameric（5） 与蛋白数一致 |
链 D
1–746（746 aa）
|
未记录 | 未记录非水小分子 | ELECTRON MICROSCOPY |
cryo-EM缓冲液
pH 7.5；200 mM NaCl, 20 mM HEPES pH 7.5, 1 mM TCEP, 0.01% NP-40
cryo-EM玻璃化条件
冷冻剂 ETHANE；Blotting 3 seconds
|
分辨率 3.64 Å |
| 8FYH G4 RNA-mediated PRC2 dimer 提交 2023-01-26 | Assembly 1 蛋白–RNA 异源复合物；蛋白 × 12 PDB 声明：tridecameric（13） 与全部聚合物一致 |
链 A
1–751（751 aa）
链 G
1–751（751 aa）
|
未记录 | ZN ZINC ION × 14 | ELECTRON MICROSCOPY |
cryo-EM缓冲液
pH 7.9；RNP complex buffer (25 mM HEPES pH 7.9, 50 mM KCl, 2 mM MgCl2, 10% glycerol, and 1mM TCEP)
EM preparation buffer I (25 mM HEPES pH 7.9, 50 mM KCl, 2.5% glycerol, and 1mM TCEP)
EM preparation buffer II (25 mM HEPES pH 7.9, 50 mM KCl, 2.5% glycerol, 0.01%NP-40, and 1mM TCEP).
cryo-EM玻璃化条件
冷冻剂 ETHANE；3s of single side blotting
|
分辨率 3.40 Å |
| 8T9G Automethylated PRC2 dimer bound to nucleosome 提交 2023-06-23 | Assembly 1 蛋白–DNA 异源复合物；蛋白 × 19 PDB 声明：21-meric（21） 与全部聚合物一致 |
链 C
2–751（750 aa）
链 I
2–751（750 aa）
|
未记录 | SAH S-ADENOSYL-L-HOMOCYSTEINE × 2 | ELECTRON MICROSCOPY |
cryo-EM缓冲液
pH 7.8
cryo-EM玻璃化条件
冷冻剂 ETHANE
|
分辨率 6.20 Å |
| 8TAS PRC2 monomer bound to nucleosome 提交 2023-06-27 | Assembly 1 蛋白–DNA 异源复合物；蛋白 × 13 PDB 声明：pentadecameric（15） 与全部聚合物一致 |
链 E
2–751（750 aa）
|
未记录 | SAH S-ADENOSYL-L-HOMOCYSTEINE × 1 | ELECTRON MICROSCOPY |
cryo-EM缓冲液
pH 7.8
cryo-EM玻璃化条件
冷冻剂 ETHANE
|
分辨率 4.10 Å |
| 8TB9 PRC2-J119-450 monomer bound to H1-nucleosome 提交 2023-06-28 | Assembly 1 蛋白–DNA 异源复合物；蛋白 × 15 PDB 声明：heptadecameric（17） 与全部聚合物一致 |
链 E
2–751（750 aa）
|
未记录 | SAH S-ADENOSYL-L-HOMOCYSTEINE × 1 | ELECTRON MICROSCOPY |
cryo-EM缓冲液
pH 7.8
cryo-EM玻璃化条件
冷冻剂 ETHANE
|
分辨率 4.00 Å |
| 8VMI PRC2_AJ119-450 bound to H3K4me3 提交 2024-01-13 | Assembly 1 蛋白异源复合物 异源复合物；蛋白 × 9 PDB 声明：nonameric（9） 与蛋白数一致 |
链 C
1–746（746 aa）
|
未记录 | ZN ZINC ION × 7 | ELECTRON MICROSCOPY |
cryo-EM缓冲液
pH 7.5
cryo-EM玻璃化条件
冷冻剂 ETHANE
|
分辨率 3.10 Å |
| 8VML PRC2_AJ1-450 bound to H3K4me3 提交 2024-01-13 | Assembly 1 蛋白异源复合物 异源复合物；蛋白 × 7 PDB 声明：heptameric（7） 与蛋白数一致 |
链 C
1–746（746 aa）
|
未记录 | 未记录非水小分子 | ELECTRON MICROSCOPY |
cryo-EM缓冲液
pH 7.5
cryo-EM玻璃化条件
冷冻剂 ETHANE
|
分辨率 3.50 Å |
| 8VNV PRC2_AJ1-450 bound to H3K36me3 with histone H3 tail engaged 提交 2024-01-13 | Assembly 1 蛋白–DNA 异源复合物；蛋白 × 7 PDB 声明：nonameric（9） 与全部聚合物一致 |
链 C
2–751（750 aa）
|
未记录 | SAH S-ADENOSYL-L-HOMOCYSTEINE × 1 | ELECTRON MICROSCOPY |
cryo-EM缓冲液
pH 7.9
cryo-EM玻璃化条件
冷冻剂 ETHANE
|
分辨率 3.10 Å |
| 8VNZ PRC2_AJ1-450 bound to H3K36me3-modified nucleosome with histone H3 tail disengaged 提交 2024-01-14 | Assembly 1 蛋白异源复合物 异源复合物；蛋白 × 6 PDB 声明：hexameric（6） 与蛋白数一致 |
链 C
1–746（746 aa）
|
未记录 | SAH S-ADENOSYL-L-HOMOCYSTEINE × 1 | ELECTRON MICROSCOPY |
cryo-EM缓冲液
pH 7.5
cryo-EM玻璃化条件
冷冻剂 ETHANE
|
分辨率 3.50 Å |
| 9C8U Human PRC2 - RvLEAM (short) (1:6 molar ratio), cross-linked 10 min 提交 2024-06-13 | Assembly 1 蛋白异源复合物 异源复合物；蛋白 × 6 PDB 声明：hexameric（6） 与蛋白数一致 |
链 A
2–751（750 aa）
|
未记录 | ZN ZINC ION × 7 | ELECTRON MICROSCOPY |
cryo-EM缓冲液
pH 7.5
cryo-EM玻璃化条件
冷冻剂 ETHANE
|
分辨率 3.10 Å |
| 9DCH Single-stranded RNA-mediated PRC2 dimer 提交 2024-08-26 | Assembly 1 蛋白–RNA 异源复合物；蛋白 × 12 PDB 声明：tridecameric（13） 与全部聚合物一致 |
链 A
2–751（750 aa）
链 H
2–751（750 aa）
|
未记录 | ZN ZINC ION × 14 | ELECTRON MICROSCOPY |
cryo-EM缓冲液
pH 7.9；RNP complex buffer (25 mM HEPES pH 7.9, 50 mM KCl, 2 mM MgCl2, 10% glycerol, and 1 mM TCEP)
EM preparation buffer I (25 mM HEPES pH 7.9, 50 mM KCl, 2.5% glycerol, and 1 mM TCEP)
EM preparation buffer II (25 mM HEPES pH 7.9, 50 mM KCl, 2.5% glycerol, 0.01%NP-40, and 1 mM TCEP).
cryo-EM玻璃化条件
冷冻剂 ETHANE；2-3s of single side blotting
|
分辨率 3.40 Å |